Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase

Condition(s) studied

Investigational drug(s) / intervention(s)

Observation: Monitor every 6 months

Antiviral treatment: Receive first-line antiviral treatment, including entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir amibufenamide or peginterferon

Study summary

Chronic hepatitis B virus (HBV) infection remains a global public health burden around the world. Investigating the disease process of chronic hepatitis B (CHB) is essential to individual management in clinical practice. According to American Association for the Study of Liver Diseases (AASLD) 2018 Hepatitis B Guidance, CHB can be classified into four phases: immune-tolerant CHB, HBeAg-positive immune active CHB, inactive CHB and hepatitis B e antigen (HBeAg)-negative immune active CHB. Antiviral therapy is recommended in patients with HBeAg-positive or -negative immune active CHB patients to reduce the incidence of liver cirrhosis and hepatocellular carcinoma, while periodic monitoring is recommended for inactive carrier and immune-tolerant CHB patients. However, a substantial proportion of patients fall into an indeterminate phase whose serum HBV DNA and alanine aminotransferase levels do not fit well into these well-described phases. Most of CHB patients with indeterminate phase are HBeAg negative. However, the clinical outcomes of these patients remain unclear. Therefore, the purpose of this study is to investigate the clinical outcomes of HBeAg-negative chronic hepatitis B patients with indeterminate phase.

Eligibility

Primary outcome measure(s)

• The incidence of hepatocellular carcinoma at 240 weeks — 240 weeks
• The HBsAg clearance rate at 240 weeks — 240 weeks

Trial sites (5)

More The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials in China

Other trials for the same condition